A breast cancer diagnosis can be terrifying, but one type of early-stage disease is noninvasive and has high survival odds.

Facing a breast cancer diagnosis can be an overwhelming experience, filled with uncertainty and fear, but knowledge is a ...

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced positive topline results from the pivotal ...

Adenocarcinoma in situ (AIS) of the lung —previously included in the category of "bronchioloalveolar carcinoma" (BAC)—is a subtype of lung adenocarcinoma. It tends to arise in the distal bronchioles ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

Most lung cancers are called non-small cell lung cancer (NSCLC). This group includes: adenocarcinoma squamous cell carcinoma large cell carcinoma ALK-positive lung cancer The second, smaller ...

It was also highly accurate in ... Study Unravels the Earliest Cellular Genesis of Lung Adenocarcinoma Feb. 28, 2024 — Researchers built a new atlas of lung cells, uncovering new cellular ...

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC ... cancer ...

Press Release4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral ...

Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral ImmunotherapyCompany founded by 4BIO Capital and ...

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FR?) positive, platinum-resistant ovarian cancerELAHERE represents the ...

Being able to discern a cancer cell in situ from a healthy cell without relying on a surface ... Trogenix is advancing programmes in colorectal cancer liver metastases, hepatocellular carcinoma, lung ...